{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/ViiV219590","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.","IpdDescription":"Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK’s data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"True","IpdInfoTypeCsr":"True","IpdInfoTypeProtocol":"True","IpdInfoTypeSap":"True","IpdTimeFrame":"Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","IpdUrl":"https://www.gsk.com/en-gb/innovation/trials/data-transparency/","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"This is an open-label non-blinded study","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"Yes","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Part 1 - GSK4524101 Monotherapy","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"Part 1 - GSK4524101 plus Niraparib","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"Part 1 - GSK4524101 Food Effect Cohort","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"Part 2 - GSK4524101 plus Niraparib","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"Part 2 - Niraparib","arm_group_description":"","arm_type":"Active Comparator"}],"assignment":"Sequential Assignment","brief_summary":"The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with niraparib in participants with solid tumors","conditions":[{"DisplayValue":"Cancer - Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_CANCER_OTHER","LookupValue":"Neoplasms","LookupValue_OneLinkTx":""}],"created_date":"04/06/2026 14:21:46","criteria":"Inclusion Criteria:\n  - More than or equal to (≥)18 years of age\n  - Eastern cooperative oncology group (ECOG) class 0-2\n  - Life expectancy of a minimum of 3 month\n  - Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options (Part 1).\n  - Participant has metastatic, gBRCAmut, HER2-negative or HER2-low breast cancer who has completed at most 3 or more prior lines of therapy (Part 2).\n\nExclusion Criteria:\n  - Participant has not recovered (i.e., to Grade less than or equal to [≤1] or to baseline) from prior chemotherapy-induced AEs. \n  - Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.\n  - Participant has symptomatic uncontrolled brain or leptomeningeal metastases. \n  - Participant has a known additional malignancy that progressed or required active treatment within the last 2 years \n  - Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).\n  - Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) >140 millimetres of mercury (mmHg) or diastolic BP >90 mmHg.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1/Phase 2","display_phase_internal":"PHASE_1_2","display_status":"Active, not recruiting","display_status_internal":"RECSTATUS_I_ACTIVE_NOT_REC","endpoint":"","enrollment":"42","exclusion":"","gender":"All","gender_based":"No","gender_description":"","healthy_volunteers":"No","id":"7ea1c6d7-37d2-5029-9b4c-c0984a01436a","internal":{"content":null,"contentDigest":"c6e832a12f1fb90e4b3a1475b610ac8d","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n  - More than or equal to (≥)18 years of age\n  - Eastern cooperative oncology group (ECOG) class 0-2\n  - Life expectancy of a minimum of 3 month\n  - Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options (Part 1).\n  - Participant has metastatic, gBRCAmut, HER2-negative or HER2-low breast cancer who has completed at most 3 or more prior lines of therapy (Part 2).\n\nExclusion Criteria:\n  - Participant has not recovered (i.e., to Grade less than or equal to [≤1] or to baseline) from prior chemotherapy-induced AEs. \n  - Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.\n  - Participant has symptomatic uncontrolled brain or leptomeningeal metastases. \n  - Participant has a known additional malignancy that progressed or required active treatment within the last 2 years \n  - Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).\n  - Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) >140 millimetres of mercury (mmHg) or diastolic BP >90 mmHg.","interventions":[{"arm_group_label":"Part 1 - GSK4524101 Monotherapy","intervention_description":"GSK452101 will be administered.","intervention_name":"GSK4524101","intervention_type":"Drug"},{"arm_group_label":"Part 1 - GSK4524101 plus Niraparib","intervention_description":"GSK452101 will be administered.","intervention_name":"GSK4524101","intervention_type":"Drug"},{"arm_group_label":"Part 1 - GSK4524101 Food Effect Cohort","intervention_description":"GSK452101 will be administered.","intervention_name":"GSK4524101","intervention_type":"Drug"},{"arm_group_label":"Part 2 - GSK4524101 plus Niraparib","intervention_description":"GSK452101 will be administered.","intervention_name":"GSK4524101","intervention_type":"Drug"},{"arm_group_label":"Part 1 - GSK4524101 plus Niraparib","intervention_description":"Niraparib will be administered.","intervention_name":"Niraparib","intervention_type":"Drug"},{"arm_group_label":"Part 2 - GSK4524101 plus Niraparib","intervention_description":"Niraparib will be administered.","intervention_name":"Niraparib","intervention_type":"Drug"},{"arm_group_label":"Part 2 - Niraparib","intervention_description":"Niraparib will be administered.","intervention_name":"Niraparib","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["POLQi","Niraparib","GSK4524101"],"last_follow_up_date":"06/30/2026 00:00:00","links":[],"locations":[{"City":"Dallas","Latitude":"32.9005121","CountryDisplay":"Unmapped","Longitude":"-96.7868794","Name":"GSK Investigational Site","StateDisplay":"TX","PostalCode":"75230","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"Houston","Latitude":"29.7050857","CountryDisplay":"Unmapped","Longitude":"-95.4018087","Name":"GSK Investigational Site","StateDisplay":"TX","PostalCode":"77030","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"St Louis","Latitude":"38.6212468","CountryDisplay":"Unmapped","Longitude":"-90.2526163","Name":"GSK Investigational Site","StateDisplay":"MO","PostalCode":"63110","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fairfax","Latitude":"38.864187","CountryDisplay":"Unmapped","Longitude":"-77.2577571","Name":"GSK Investigational Site","StateDisplay":"VA","PostalCode":"22031","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Antonio","Latitude":"29.5068008","CountryDisplay":"Unmapped","Longitude":"-98.5666077","Name":"GSK Investigational Site","StateDisplay":"TX","PostalCode":"78229","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7748363","CountryDisplay":"Unmapped","Longitude":"-122.3872576","Name":"GSK Investigational Site","StateDisplay":"CA","PostalCode":"94158","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"Edmonton","Latitude":"53.5179891","CountryDisplay":"Canada","Longitude":"-113.5307568","Name":"GSK Investigational Site","StateDisplay":"AB","PostalCode":"T6G 1Z2","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Toronto","Latitude":"43.6580016","CountryDisplay":"Canada","Longitude":"-79.3902855","Name":"GSK Investigational Site","StateDisplay":"ON","PostalCode":"M5G 2M9","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.4745831","CountryDisplay":"Canada","Longitude":"-73.5980739","Name":"GSK Investigational Site","StateDisplay":"QC","PostalCode":"H4A 3J1","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"Panama","Latitude":"8.537981","CountryDisplay":"Panama","Longitude":"-80.782127","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Punta Pacifica Panama City Panama","Latitude":"8.976834","CountryDisplay":"Panama","Longitude":"-79.5076464","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"N/A","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chihuahua","Latitude":"28.6197928","CountryDisplay":"Mexico","Longitude":"-106.1183999","Name":"GSK Investigational Site","StateDisplay":"Chihuahua","PostalCode":"31207","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tuxtla Gutierrez","Latitude":"16.7327493","CountryDisplay":"Mexico","Longitude":"-93.1002082","Name":"GSK Investigational Site","StateDisplay":"Chiapas","PostalCode":"29090","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"CIUDAD DE MEXICO","Latitude":"19.4368626","CountryDisplay":"Mexico","Longitude":"-99.2106745","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"11510","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Toluca","Latitude":"19.2778994","CountryDisplay":"Mexico","Longitude":"-99.6633711","Name":"GSK Investigational Site","StateDisplay":"Estado de Mexico","PostalCode":"50120","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"VitOria","Latitude":"-20.3009111","CountryDisplay":"Brazil","Longitude":"-40.3155355","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"29043-260","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"Porto Alegre","Latitude":"-30.0307294","CountryDisplay":"Brazil","Longitude":"-51.2217197","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"90020-090","StatusDisplay":"Active not recruiting","StatusDisplayInternal":"LOCSTATUS_UNMAPPED","StatusMapped":"Unmapped"},{"City":"Tijuana","Latitude":"32.5286085","CountryDisplay":"Mexico","Longitude":"-117.0220308","Name":"GSK Investigational Site","StateDisplay":"Baja California","PostalCode":"22010","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"04/06/2026 14:21:46","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors","org_study_id":"ViiV219590","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"No","fda_regulated_drug":"Yes","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 1/Phase 2","primary_compl_date":"06/30/2026 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Part 1 - Proportion of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation Period","outcome_time_frame":"Up to 28 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 – Proportion of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation Period","outcome_time_frame":"Up to 28 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation Period","outcome_time_frame":"Up to 28 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation Period","outcome_time_frame":"Up to 28 days","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation Period","outcome_time_frame":"Up to 28 days","outcome_safety_issue":null},{"outcome_description":"ORR is the percentage of participants with an Investigator-assessed confirmed complete response and confirmed partial response to treatment, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1","outcome_measure":"Part 2 - Confirmed Objective Response Rate (ORR)","outcome_time_frame":"Up to approximately 52 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"","id_type":"","id_domain":""}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Part 1 – Area Under Curve (AUC) of GSK4364973 (Metabolite of GSK4524101)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 –Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 – Time to Maximum Concentration of GSK4364973 (Metabolite of GSK4524101)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 – Half-life of GSK4364973 (Metabolite of GSK4524101) (Days)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 –Plasma Concentration of Niraparib","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 – Number of Participants with TEAEs and SAEs based on Severity beyond DLT Observation Period","outcome_time_frame":"Up to approximately 24 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 1 - Duration of TEAEs and SAEs (Days) beyond DLT Observation Period","outcome_time_frame":"Up to approximately 24 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 2 – Number of Participants with TEAEs and SAEs based on Severity","outcome_time_frame":"Up to approximately 52 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 2 - Duration of Treatment Emergent AEs and SAEs (Days)","outcome_time_frame":"Up to approximately 52 weeks","outcome_safety_issue":null},{"outcome_description":"PFS is time from randomization to progressive disease or death from any cause, whichever is earlier, as assessed via RECIST v1.1 by Investigator assessment","outcome_measure":"Part 2 – Progression-free Survival (PFS)","outcome_time_frame":"Up to approximately 52 weeks","outcome_safety_issue":null},{"outcome_description":"DOR is defined as time from first documented PR or better to disease progression (as assessed by RECIST v1.1 by investigator assessment) or death whichever is earlier for participants who have achieved a CR or PR","outcome_measure":"Part 2 - Duration of Response (DOR)","outcome_time_frame":"Up to approximately 52 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 2 –Maximum Concentration (Cmax) of GSK4364973 (Metabolite of GSK4524101)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 2 – Minimum Concentration (Cmin) of GSK4364973 (Metabolite of GSK4524101)","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Part 2 –Plasma Concentration of Niraparib","outcome_time_frame":"Up to 21 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"10/24/2023 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"ViiV219590"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}